Literature DB >> 12622624

Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis.

T Markham1, S Rogers, P Collins.   

Abstract

OBJECTIVE: To compare the efficacy of narrowband UV-B (TL-01) phototherapy with oral 8-methoxypsoralen photochemotherapy (8-MOP psoralen-UV-A [PUVA]) in patients with chronic plaque psoriasis (CPP).
DESIGN: Open, randomized, controlled study.
SETTING: Phototherapy unit in a dermatology hospital. PATIENTS: Fifty-four patients with CCP.
INTERVENTIONS: Patients received whole-body threshold erythemogenic dose of either 3-times weekly TL-01 or twice-weekly oral 8-MOP PUVA, based on minimal erythema or phototoxic doses. Patients were treated until completely clear. OUTCOME MEASURES: Number of treatments to clear, number of days in treatment, number of days in remission, and adverse effects of both therapies were assessed.
RESULTS: Forty-five patients completed the study. Those in the PUVA group required significantly fewer treatments to clear (P =.03). There was no significant difference in the number of days to clear or number of days in remission. A similar percentage of patients in the TL-01 and PUVA groups developed minimal perceptible erythema, showing that the regimens were equally erythemogenic. Asymptomatic, well-defined erythema occurred only in the PUVA group. Pruritus and polymorphic light eruption occurred equally in both groups, but only patients in the PUVA group developed nausea.
CONCLUSION: Narrowband UV-B phototherapy, used 3 times weekly, is as effective for the treatment of CPP as oral 8-MOP PUVA used twice weekly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12622624     DOI: 10.1001/archderm.139.3.325

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

1.  Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-11-01

2.  Assessment of efficacy and safety of UV-based therapy for psoriasis: a network meta-analysis of randomized controlled trials.

Authors:  Yajia Li; Ziqin Cao; Jia Guo; Qiangxiang Li; Wu Zhu; Yehong Kuang; Xiang Chen
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

Review 3.  German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

Authors:  A Nast; I Kopp; M Augustin; K B Banditt; W H Boehncke; M Follmann; M Friedrich; M Huber; C Kahl; J Klaus; J Koza; I Kreiselmaier; J Mohr; U Mrowietz; H M Ockenfels; H D Orzechowski; J Prinz; K Reich; T Rosenbach; S Rosumeck; M Schlaeger; G Schmid-Ott; M Sebastian; V Streit; T Weberschock; B Rzany
Journal:  Arch Dermatol Res       Date:  2007-05-12       Impact factor: 3.017

4.  Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.

Authors:  Maeve Lynch; Tomás B Ahern; Irene Timoney; Cheryl Sweeney; Genevieve Kelly; Rosalind Hughes; Anne-Marie Tobin; Donal O'Shea; Brian Kirby
Journal:  Trials       Date:  2016-01-15       Impact factor: 2.279

5.  The efficacy and safety of phototherapy in geriatric patients: a retrospective study.

Authors:  Isil Bulur; Hilal Kaya Erdogan; Ayse Esra Aksu; Tekden Karapınar; Zeynep Nurhan Saracoglu
Journal:  An Bras Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.896

6.  A Perspective on the Use of NB-UVB Phototherapy vs. PUVA Photochemotherapy.

Authors:  Sally H Ibbotson
Journal:  Front Med (Lausanne)       Date:  2018-07-02

7.  Serum levels of folate, 25-hydroxyvitamin D3 and cobalamin during UVB phototherapy: findings in a large prospective trial.

Authors:  B Weber; R Marculescu; S Radakovic; A Tanew
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-10-08       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.